|
IRAK4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.66070004812025E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.65799999998872E-06 |
| Normal-vs-Stage2 |
6.44349999999738E-05 |
| Normal-vs-Stage3 |
2.1112001036272E-10 |
| Normal-vs-Stage4 |
3.87479999996998E-06 |
| Stage1-vs-Stage2 |
5.389600E-01 |
| Stage1-vs-Stage3 |
1.441740E-03 |
| Stage1-vs-Stage4 |
2.167200E-01 |
| Stage2-vs-Stage3 |
1.225180E-01 |
| Stage2-vs-Stage4 |
6.587800E-01 |
| Stage3-vs-Stage4 |
3.009800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.55920001541222E-09 |
| Normal-vs-AfricanAmerican |
1.257600E-03 |
| Normal-vs-Asian |
4.124400E-03 |
| Caucasian-vs-AfricanAmerican |
5.812200E-01 |
| Caucasian-vs-Asian |
4.154500E-02 |
| AfricanAmerican-vs-Asian |
3.989200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.54209999950695E-07 |
| Normal-vs-Female |
6.12039996461533E-09 |
| Male-vs-Female |
8.487600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.5762099999983E-05 |
| Normal-vs-Age(41-60Yrs) |
1.84089999910597E-08 |
| Normal-vs-Age(61-80Yrs) |
4.79170003675478E-09 |
| Normal-vs-Age(81-100Yrs) |
1.443360E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.335210E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.504270E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.297800E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.743200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.586800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.788000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.972200E-04 |
| Classical-VS-Follicular |
4.369800E-01 |
| Classical-VS-Other |
6.044200E-01 |
| Classical-VS-Normal |
1.21750000003917E-06 |
| Tall-VS-Follicular |
5.795700E-03 |
| Tall-VS-Other |
1.540040E-01 |
| Tall-VS-Normal |
2.05020000976219E-10 |
| Follicular-VS-Other |
8.835000E-01 |
| Follicular-VS-Normal |
2.12689999999904E-05 |
| Other-VS-Normal |
1.497610E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.21940000319398E-08 |
| Normal-vs-N1 |
3.0185999999599E-06 |
| N0-vs-N1 |
7.164600E-01 |
|
|
